[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Basel\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":172},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,75,97,122,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100295306","cascade-genetic-testing-for-hereditary-breastovarian-cancer-and-lynch-syndrome-in-switzerland-100295306",false,"NCT03124212","Cascade Genetic Testing for Hereditary Breast\u002FOvarian Cancer and Lynch Syndrome in Switzerland","CASCADE","Inclusion Criteria:\n\n1. Carrier of a mutation associated with HBOC or LS\n2. Have at least one living blood relative\n3. Men and women\n4. 18 years old and older\n5. Mentally and physically able to provide informed consent\n6. Can read and speak German or French or Italian or English\n7. Currently living in Switzerland.\n\nExclusion Criteria:\n\n1. Carriers of unclassified variants (VUS) in BRCA1, BRCA2 or MLH1, MSH2, MSH6, PMS2, EPCAM genes\n2. Not living in Switzerland\n3. Patients who are critically ill and cannot complete the CASCADE survey\n4. Participants who are institutionalized (e.g., nursing homes) or incarcerated","ALL","18 Years",{"count":19,"type":20},700,"ESTIMATED","OBSERVATIONAL","Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer cases in Switzerland and affect more than 12,000 individuals annually. Several hundred of these patients are likely to carry known genetic mutations associated with HBOC or LS. Genetic testing for hereditary susceptibility to cancer can prevent many cancer deaths through early identification and engagement in high-risk management care that involves intensive surveillance, chemoprevention and\u002For prophylactic surgery. However, current rates of genetic testing indicate that many Swiss mutation carriers and their family members do not use cancer genetic services (counseling and\u002For testing), either due to lack of coordination of care or due to lack of communication about the mutation among family members.\n\nCascade screening identifies and tests family members of a known mutation carrier. It determines whether asymptomatic family members are carriers of the identified mutation and proposes management options to reduce harmful outcomes. Robust evidence of basic science and descriptive population-based studies in Switzerland support the necessity of cascade screening for HBOC and LS. However, translation of this knowledge into public health interventions is lacking.\n\nSpecific Aims of the CASCADE study are:\n\n1. Survey Index Patients diagnosed with HBOC or LS from clinic-based genetic testing records and determine their cancer status and surveillance practices; needs for coordination of medical care; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to serve as advocates for cancer genetic services for blood relatives.\n2. Survey first- and second-degree relatives, and first cousins identified from pedigrees and\u002For family history records of HBOC and LS Index Patients and determine their cancer and mutation status; cancer surveillance practices; needs for coordination of medical care; barriers and facilitators to using cancer genetic services; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to participate in a study designed to increase use of cancer genetic services.\n3. Explore the influence of patient-provider communication about genetic cancer risk on patient-family communication and the acceptability of a family-based communication, coping, and decision support intervention with focus group(s) of mutation carriers and blood relatives.",[24,25],"Hereditary Breast and Ovarian Cancer","Lynch Syndrome",[27,28,29,30],"mutation carrier","blood relative","genetic testing","family-based cohort","RECRUITING","2026-05-10",{"date":34,"type":35},"2026-05-13","ACTUAL",{"date":37,"type":35},"2017-04-01",{"date":39,"type":20},"2035-01-31",{"name":41,"class":42},"University of Basel","OTHER",9,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100591022","pilot-study-for-the-comparison-of-biomarkers-between-regular-cannabis-users-and-non-users-100591022","NCT06975020","Pilot-Study for the Comparison of Biomarkers Between Regular Cannabis Users and Non-Users","CANBiome: Pilot-Study for the Comparison of Biomarkers Between Regular Cannabis Users and Non-Users","CANBiome","Inclusion Criteria:\n\n* Experience of smoking cannabis products, on average once a week. This may be in combination with tobacco.\n* Age 18-65 years Possession of driving license in at least one of the categories A, B, A1; B1, F, G or M\n* Sufficient knowledge of German\n* No cannabis inhalation or nicotine consumption on study day\n* No alcohol consumption within the last 24 h\n\nExclusion Criteria:\n\n* Participation in a trial with investigational drugs within 30 days\n* Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)\n* Pregnancy or breastfeeding\n* Intake of CYP2C9, CYP2C19, and CYP3A4-inducers in the last 4 weeks before the study visit, e.g. rifampicin (antibiotic), carbamazepine (anticonvulsant), phenobarbital (anticonvulsant), phenytoin (anticonvulsant) or inhibitors, such as amiodarone (class III antiarrhythmic medication), antifungal drugs such as fluconazole, miconazole, voriconazole and itraconazole, antibiotics such as clarithromycin and sulfamethoxazole, ritonavir (protease inhibitor) and grapefruit juice.\n* The following conditions: vasopressin deficiency, pituitary tumor, active malignancy, severe hyponatremia requiring treatment, congestive heart failure, liver cirrhosis.",true,"65 Years",{"count":55,"type":20},120,"INTERVENTIONAL",[58],"NA","The relevance of driving under the influence of cannabis is becoming increasingly important in the context of legalization. However, the measurement of tetrahydrocannabinol (THC) blood concentration is an inadequate marker for assessing driving impairment. Currently, there is no reliable marker available for estimating the time of last cannabis inhalation, which would provide a promising tool for regulating driving under the influence of cannabis. This pilot study aims to explore potential biomarkers and factors that could approximate the timing of the last cannabis inhalation, with emphasis on the potential explanation of interindividual differences in THC pharmacokinetics and -dynamics. The results will assist future research aimed at improving the ability to distinguish between impaired and unimpaired cannabis users in road traffic. These findings are of significant importance for road safety and for society at large, as they may provide more objective markers for cannabis inhalation, thereby permitting a methodologically sound evaluation of driving under the influence of cannabis.",[61],"Driving Under the Influence of Cannabis",[63,64,65],"Cannabis","Driving","Biomarker","2025-12-18",{"date":68,"type":35},"2025-12-26",{"date":70,"type":35},"2025-12-19",{"date":72,"type":20},"2027-01-01",{"name":41,"class":42},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":56,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100587690","neurological-and-physiological-effects-of-animal-assisted-therapy-for-patients-in-a-minimally-conscious-state-100587690","NCT06931665","Neurological and Physiological Effects of Animal-assisted Therapy for Patients in a Minimally Conscious State","Neurological and Physiological Effects of Animal-assisted Therapy for Patients in a Minimally Conscious State: a Randomized, Controlled Cross-over Study","EMCS","Inclusion Criteria:\n\n* Inpatients in one of the study sites\n* Acquired brain injury resulting from either traumatic or non-traumatic events\n* Diagnosis of MCS defined by CRS-R according to the Aspen criteria (Giacino, 2005)\n* Informed consent as documented by signature by the patient's legal representative\n* Physiologically stable\n* Aged 18 or over\n\nExclusion Criteria:\n\n* Phobia or allergies to any of the involved animals\n* Medical contraindications: acute or chronic disease (e.g. chronic pain, hypertension, heart disease, renal disease, liver disease, diabetes)\n* Radical changes in medication (decision made with responsible physician)",{"count":84,"type":20},26,[58],"This study aims to explore the impact of Animal Assisted Therapy (AAT) on brain signal complexity in patients with minimally conscious state (MCS) by analyzing electroencephalogram (EEG) entropy. MCS patients typically exhibit reduced brain entropy compared to healthy individuals, indicating lower brain complexity. The study will assess whether AAT can enhance this complexity, which is crucial for understanding consciousness levels. Entropy, a measure of randomness in brain activity, will be used to evaluate AAT's effectiveness. In addition, electrocardiography (ECG), electrodermal activity (EDA) and behavioral measurements will also be collected.",[88],"Minimally Conscious State","2025-12-11",{"date":66,"type":35},{"date":92,"type":35},"2025-07-08",{"date":94,"type":20},"2027-04",{"name":41,"class":42},2,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":56,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":74},"100573861","phase-2-cross-over-study-on-the-influence-of-fampridine-on-working-memory-in-mild-to-moderate-depression-100573861","NCT06751784","Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression","Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression","FamD_2025","Inclusion Criteria:\n\n* Male or female\n* Major depressive episode confirmed by the Mini-DIPS. Currently mild to moderate (MADRS: 7-30).\n* Normotensive (BP: 90\u002F60mmHg - 140\u002F90mmHg). Sufficiently treated hypertensive subjects will be included.\n* BMI: 19 - 34,9 kg\u002Fm2\n* Age: 18 - 55 years\n* Fluent in German\n* IC as documented by signature\n\nExclusion Criteria:\n\n* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to 4-aminopyridine\n* Use of potassium channel blockers within the last 3 months\n* Treatment with OCT 2 inhibitors and -substrates (e.g. cimetidine, propranolol)\n* Treatment with antidepressants or antipsychotics within the last 3 months and throughout the study period\n* Current intake of psychoactive drugs (e.g. benzodiazepines, antidepressants, neuroleptics).\n* Other acute or chronic psychiatric disorder (e.g. psychosis, somatoform disorder, alcohol or drug abuse disorder)\n* Cognitive impairment (MoCA score \\\u003C 25)\n* MADRS item 10 \\> 1 (suicidal tendency)\n* Risk of lowered seizure threshold (due to e.g. sleep deprivation, withdrawal of alcohol after alcohol abuse, hyponatraemia)\n* History of seizures\n* Acute cerebrovascular condition\n* Acute renal failure or severe renal insufficiency (creatinine clearance \\\u003C 30 ml\u002Fmin per 1.73 m2)\n* Bradycardia \\\u003C 50\u002Fmin during clinical examination.\n* History of malignant cancers\n* Walking problems (e.g. due to dizziness)\n* Other clinically significant concomitant disease states (e.g. hepatic dysfunction, cardiovascular disease, diabetes, asthma)\n* Clinically significant laboratory or ECG abnormality that could be a safety issue in the study\n* Severe somatic or neurological comorbidities\n* Smoking including all nicotine containing smoking systems and devices (\\>10 cigarettes\u002Funits per day). Failure to withstand a test day without craving, due to regular consummation patterns.\n* Pregnancy or breast feeding. Intention to become pregnant during the study participation.\n* Known or suspected non-compliance\n* Inability to follow the procedures of the study, e.g. due to language or psychological problems of the participant\n* Participation in another study with an investigational drug within the 30 days preceding and during the present study\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons","55 Years",{"count":107,"type":20},38,[109],"PHASE2","Cognitive deficits, including working memory deficits, are often present in depression and there are currently no effective pharmacological treatments targeting working memory deficits. Papassotiropoulos et al. (2024) has recently demonstrated that fampridine, a potassium channel blocker, can enhance working memory in healthy individuals with lower baseline performance, suggesting it may hold potential for addressing cognitive deficits in clinical populations. The primary aim of this study is to evaluate whether fampridine improves working memory performance in mild to moderate depression",[112,113],"Working Memory","Mild to Moderate Depression","2025-12-04",{"date":116,"type":35},"2025-12-12",{"date":118,"type":35},"2025-05-22",{"date":120,"type":20},"2026-07",{"name":41,"class":42},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":56,"phases":134,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":96},"100486013","animal-assisted-trauma-focused-therapy-for-children-and-adolescents-100486013","NCT05608551","Animal-assisted Trauma-focused Therapy for Children and Adolescents","Effects of a Psychotherapy Group Program for Children and Adolescents With Post-traumatic Stress Symptoms","AA TF-CBT","Inclusion Criteria:\n\n* Age between 9 and 17 years\n* experienced a traumatic event\n* remembers at least one traumatic event\n* Suffering from posttraumatic stress symptoms (screened via the CATS-2; cut-off ≥ 21; cut-off must be reached by either participant or caregiver)\n* Basic knowledge of child and parents in German to be able to understand content of the session and to fill in questionnaires\n* Informed consent (given by legal guardian for participants younger than 14 years)\n* Positive or neutral attitude towards animals\n\nExclusion Criteria:\n\n* Inability to complete questionnaires due to lack of language skills or cognitive impairment\n* Diagnosed autism spectrum disorder; Exclusion only if interaction with others and group ability is limited due to autism\n* Reported significant impairment or safety issue (e.g., active suicidal ideation, acute psychosis)\n* Known abuse of substances used for emotion regulation (e.g. cannabis, alcohol, other hard drugs)\n* Fear of domestic animals\n* Allergic reactions to domestic animals\n* Reported aggressive behavior towards animals in the past","9 Years","17 Years",{"count":133,"type":20},80,[58],"The study aims to investigate how the inclusion of an animal into a trauma-focused group therapy program (TF-CBT) affects therapy motivation of children and adolescents suffering from post-traumatic stress. 80 children and adolescents aged 9 to 17 years are recruited for the study. Participants must have experienced at least one traumatic event leading to post-traumatic stress symptoms. Participants are randomly allocated to one of two groups: animal-assisted trauma-focused therapy (AA TF-CBT) or standard trauma-focused therapy (TF-CBT). Parallel to the groups the parents\u002Fguardians of the participating children and adolescents take part in three parent meetings.\n\nThe results of the study help to gain insights into how the inclusion of animals in trauma-focused psychotherapy can contribute to children and adolescents attending therapy, being more motivated in therapy, and can successfully complete therapy.",[137,138],"Motivation","Alliance, Therapeutic",[140,141,142,143],"PTSD","animal-assisted therapy","trauma-focused therapy","motivation","2024-07-17",{"date":146,"type":35},"2024-07-19",{"date":148,"type":35},"2022-10-01",{"date":150,"type":20},"2028-07-31",{"name":41,"class":42},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":130,"maxAge":131,"enrollmentInfo":160,"targetDuration":4,"studyType":56,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":74},"100468824","canine-assisted-psychotherapy-motivation-alliance-100468824","NCT05384808","Canine-assisted Psychotherapy Motivation Alliance","Effects of the Inclusion of a Dog in Psychotherapy on Children's Alliance and Treatment Motivation","CAP","Inclusion Criteria for children and adolescents: :\n\n* Age between 9 and 17 years\n* Children are seeing the therapist for the first time\n* Basic knowledge of child and parents in either German or English to be able to fill in questionnaires\n* Informed consent given by legal guardian\n* Positive or neutral attitude towards dogs\n\nExclusion Criteria for children and adolescents: :\n\n* acute psychosis; early childhood autism\n* diagnosed developmental disorder or intellectual delay; if not diagnosed, exclusion when questionnaires cannot be completed due to development level\n* fear of dogs\n* allergic reactions to dogs\n* reported aggressive behavior towards animals in the past\n\nInclusion criteria for therapists:\n\n* working with an own therapy dog\n* completed therapy training or if not completed far advanced therapy training under supervision\n* working with children and adolescents aged 9 to 17 years\n\nExclusion criteria for therapists:\n\n* not working with an own therapy dog\n* no completed or far advanced therapy training\n* not working with children and adolescents aged 9 to 17 years",{"count":161,"type":20},150,[58],"The aim of the study is to investigate the needed extent and the way a dog is integrated into psychotherapeutic interventions for them to be motivating and alliance building for children and adolescents with psychiatric disorders aged 9 to 17 years old. Specifically, we want to elaborate if the dog needs to be integrated into the therapy in a form that it is part of the therapeutic context or if the presence of the dog without being part of the therapeutic context per se is beneficial.",[137,138],{"date":166,"type":35},"2024-07-18",{"date":168,"type":35},"2022-06-01",{"date":170,"type":20},"2028-12-31",{"name":41,"class":42},""]